Related Experiment Videos
Primary coenzyme Q10 deficiency and the brain.
Ali Naini1, Vernice-Jackson Lewis, Michio Hirano
1Department of Neurology, Columbia University College of Physicians & Surgeons, New York, NY 10032, USA. abn2@columbia.edu
Biofactors (Oxford, England)
|December 30, 2003
Summary
Primary Coenzyme Q10 (CoQ10) deficiency causes cerebellar ataxia, treatable with CoQ10 therapy. The cerebellum shows selective vulnerability to CoQ10 deficiency, with the lowest CoQ10 levels observed in both human and rat brains.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Coenzyme Q10 (CoQ10) is crucial for cellular energy production.
- Primary CoQ10 deficiency is a rare genetic disorder.
- Cerebellar ataxia is a debilitating neurological condition.
Purpose of the Study:
- To establish cerebellar ataxia as a clinical syndrome resulting from primary CoQ10 deficiency.
- To investigate the regional distribution of CoQ10 in the brain.
- To assess the therapeutic effect of CoQ10 supplementation.
Main Methods:
- Clinical evaluation of 19 patients with cerebellar ataxia.
- Measurement of CoQ10 and CoQ9 levels in brain regions of rats and human subjects.
- Assessment of CoQ10 levels in blood and visceral tissues before and after oral CoQ10 administration in rats.
Main Results:
- 19 patients with cerebellar ataxia and atrophy were identified with primary CoQ10 deficiency, responsive to CoQ10 therapy.
- The cerebellum exhibited the lowest CoQ10 levels among rat brain regions studied.
- Oral CoQ10 administration significantly increased CoQ10 in blood and liver, but not brain tissue.
- Human cerebellum also showed the lowest CoQ10 concentration.
Conclusions:
- Primary CoQ10 deficiency causes a specific ataxic syndrome with selective cerebellar vulnerability.
- CoQ10 therapy is effective for this condition.
- Brain CoQ10 levels are not significantly increased by oral CoQ10 supplementation, suggesting limited blood-brain barrier penetration or different regulatory mechanisms.